Search for a trial

Can metformin prevent endothelial ischemia and reperfusion injury?
The metformin-FMD trial.

To study the protective effect of pre-treatment with metformin on flow mediated dilation after 20 minutes ischemia and 20 minutes reperfusion. If metformin treatment indeed limits endothelial IR-injury, a second study will be performed in the same…

Short term statin treatment and endothelial dysfunction due to ischemia and reperfusion injury

To study the protective effect of pretreatment (both 3 day and 7 day) with rosuvastatin and atorvastatin on flow mediated dilation after 15 minutes ischemia and 15 minutes reperfusion.

Perioperative esmolol infusion for haemodynamic stability during major vascular surgery.

Primary Objective: comparing hemodynamic stability provided by titration of esmolol in addition to standard perioperative care including low-dose metoprolol to placebo and standard care.Secondary Objective(s): -comparing the incidence of…

A phase 4, monocenter, randomized, double-blind, comparator-controlled, 3-armed parallel mechanistic intervention trial to assess the effect of 8-week empagliflozin (SGLT-2 inhibitor) monotherapy, followed by 8-week empagliflozin and linagliptin (DPP-4 inhibitor) combination therapy versus 8-week linagliptin monotherapy, followed by 8-week linagliptin and empagliflozin combination therapy versus 8-week gliclazide (Sulfonylurea derivate), followed by 8-week gliclazide intensification therapy on r

To examine the effects of mono- and combination therapy with linagliptin and empagliflozine on renal hemodynamics

Tailoring P2Y12 Inhibiting Therapy in Patients requiring Oral Anticoagulation after undergoing Percutaneous Coronary Intervention: The Switching Anti-Platelet and Anti-Coagulant Therapy - 2 Study

The aim of this study is to assess the pharmacodynamic effects of different P2Y12 inhibiting therapy (clopdiogrel vs ticagrelor) in patients at high risk for HPR identified according to the ABCD-GENE score in PCI treated patients also requiring OAC…

Genotype-guided strategy for antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease.

This study has been transitioned to CTIS with ID 2024-518122-33-00 check the CTIS register for the current data. The primary aim of the GENPAD study is to evaluate the ability of genotype-guided antithrombotic treatment to reduce adverse clinical…

A randomized trial of the effect of antiplatelet therapy (Aspirin, Aspirin and Clopidogrel or Ticagrelor) on the occurrence of atherothrombotic events following lower extremity peripheral transluminal angioplasty.

Our main goal is to establish whether there is difference in the effect between the use of aspirin, dualtherapy aspirin/clopidogrel, or ticagrelor on the occurrence of atherothrombotic events in patients following lower extremity peripheral…